These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 31868526)

  • 1. Cyclophilin inhibition as a potential treatment for nonalcoholic steatohepatitis (NASH).
    Ure DR; Trepanier DJ; Mayo PR; Foster RT
    Expert Opin Investig Drugs; 2020 Feb; 29(2):163-178. PubMed ID: 31868526
    [No Abstract]   [Full Text] [Related]  

  • 2. A Pan-Cyclophilin Inhibitor, CRV431, Decreases Fibrosis and Tumor Development in Chronic Liver Disease Models.
    Kuo J; Bobardt M; Chatterji U; Mayo PR; Trepanier DJ; Foster RT; Gallay P; Ure DR
    J Pharmacol Exp Ther; 2019 Nov; 371(2):231-241. PubMed ID: 31406003
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cyclophilin inhibition as potential therapy for liver diseases.
    Naoumov NV
    J Hepatol; 2014 Nov; 61(5):1166-74. PubMed ID: 25048953
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of NV556, a Novel Cyclophilin Inhibitor, as a Potential Antifibrotic Compound for Liver Fibrosis.
    Simón Serrano S; Grönberg A; Longato L; Rombouts K; Kuo J; Gregory M; Moss S; Elmér E; Mazza G; Gallay P; Pinzani M; Hansson MJ; Massoumi R
    Cells; 2019 Nov; 8(11):. PubMed ID: 31717385
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mice lacking cyclophilin B, but not cyclophilin A, are protected from the development of NASH in a diet and chemical-induced model.
    Stauffer WT; Goodman AZ; Bobardt M; Ure DR; Foster RT; Gallay P
    PLoS One; 2024; 19(3):e0298211. PubMed ID: 38427624
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cyclophilin D knockout significantly prevents HCC development in a streptozotocin-induced mouse model of diabetes-linked NASH.
    Stauffer WT; Bobardt M; Ure DR; Foster RT; Gallay P
    PLoS One; 2024; 19(4):e0301711. PubMed ID: 38573968
    [TBL] [Abstract][Full Text] [Related]  

  • 7. From chemical tools to clinical medicines: nonimmunosuppressive cyclophilin inhibitors derived from the cyclosporin and sanglifehrin scaffolds.
    Sweeney ZK; Fu J; Wiedmann B
    J Med Chem; 2014 Sep; 57(17):7145-59. PubMed ID: 24831536
    [TBL] [Abstract][Full Text] [Related]  

  • 8. GS-0976 (Firsocostat): an investigational liver-directed acetyl-CoA carboxylase (ACC) inhibitor for the treatment of non-alcoholic steatohepatitis (NASH).
    Alkhouri N; Lawitz E; Noureddin M; DeFronzo R; Shulman GI
    Expert Opin Investig Drugs; 2020 Feb; 29(2):135-141. PubMed ID: 31519114
    [No Abstract]   [Full Text] [Related]  

  • 9. Multi-drug approaches to NASH: what's in the development pipeline?
    Johnston MP; Patel J; Byrne CD
    Expert Opin Investig Drugs; 2020 Feb; 29(2):143-150. PubMed ID: 31524533
    [No Abstract]   [Full Text] [Related]  

  • 10. Chymase as a Possible Therapeutic Target for Amelioration of Non-Alcoholic Steatohepatitis.
    Takai S; Jin D
    Int J Mol Sci; 2020 Oct; 21(20):. PubMed ID: 33066113
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Elafibranor: a potential drug for the treatment of nonalcoholic steatohepatitis (NASH).
    Westerouen Van Meeteren MJ; Drenth JPH; Tjwa ETTL
    Expert Opin Investig Drugs; 2020 Feb; 29(2):117-123. PubMed ID: 31523999
    [No Abstract]   [Full Text] [Related]  

  • 12. The nonalcoholic steatohepatitis (NASH) drug development graveyard: established hurdles and planning for future success.
    Drenth JPH; Schattenberg JM
    Expert Opin Investig Drugs; 2020 Dec; 29(12):1365-1375. PubMed ID: 33074035
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pegbelfermin (BMS-986036): an investigational PEGylated fibroblast growth factor 21 analogue for the treatment of nonalcoholic steatohepatitis.
    Verzijl CRC; Van De Peppel IP; Struik D; Jonker JW
    Expert Opin Investig Drugs; 2020 Feb; 29(2):125-133. PubMed ID: 31899984
    [No Abstract]   [Full Text] [Related]  

  • 14. Cyclophilin-D inhibition in neuroprotection: dawn of a new era of mitochondrial medicine.
    Uchino H; Hatakeyama K; Morota S; Tanoue T; Nishiyama T; Usui D; Taguchi C; Suzuki M; Hansson MJ; Elmér E
    Acta Neurochir Suppl; 2013; 118():311-5. PubMed ID: 23564156
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeting CCR2/5 in the treatment of nonalcoholic steatohepatitis (NASH) and fibrosis: opportunities and challenges.
    Lefere S; Devisscher L; Tacke F
    Expert Opin Investig Drugs; 2020 Feb; 29(2):89-92. PubMed ID: 31952447
    [No Abstract]   [Full Text] [Related]  

  • 16. Pathophysiology of Nonalcoholic Fatty Liver Disease/Nonalcoholic Steatohepatitis.
    Manne V; Handa P; Kowdley KV
    Clin Liver Dis; 2018 Feb; 22(1):23-37. PubMed ID: 29128059
    [TBL] [Abstract][Full Text] [Related]  

  • 17. NASH (nonalcoholic steatohepatitis), diabetes, and macrovascular disease: multiple chronic conditions and a potential treatment at the metabolic root.
    Colca J
    Expert Opin Investig Drugs; 2020 Feb; 29(2):191-196. PubMed ID: 31928475
    [No Abstract]   [Full Text] [Related]  

  • 18. Potent nonimmunosuppressive cyclophilin inhibitors with improved pharmaceutical properties and decreased transporter inhibition.
    Fu J; Tjandra M; Becker C; Bednarczyk D; Capparelli M; Elling R; Hanna I; Fujimoto R; Furegati M; Karur S; Kasprzyk T; Knapp M; Leung K; Li X; Lu P; Mergo W; Miault C; Ng S; Parker D; Peng Y; Roggo S; Rivkin A; Simmons RL; Wang M; Wiedmann B; Weiss AH; Xiao L; Xie L; Xu W; Yifru A; Yang S; Zhou B; Sweeney ZK
    J Med Chem; 2014 Oct; 57(20):8503-16. PubMed ID: 25310383
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bioactive Lipid Species and Metabolic Pathways in Progression and Resolution of Nonalcoholic Steatohepatitis.
    Musso G; Cassader M; Paschetta E; Gambino R
    Gastroenterology; 2018 Aug; 155(2):282-302.e8. PubMed ID: 29906416
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The molecular basis for current targets of NASH therapies.
    Qureshi K; Neuschwander-Tetri BA
    Expert Opin Investig Drugs; 2020 Feb; 29(2):151-161. PubMed ID: 31847612
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.